Area of research
Hematology · Oncology
Research interest
Research interests include Medicine, Internal medicine, Myeloid leukemia, Leukemia, Decitabine, and Hypomethylating agent.
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Functional genomic landscape of acute myeloid leukaemia
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017
Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms
Chronic Myelogenous Leukemia, Version 1.2015
Chronic Myelogenous Leukemia, Version 1.2014
First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)